Hologic, Inc. Share Price

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
75.98 USD +0.36% Intraday chart for Hologic, Inc. +0.80% +6.34%
Sales 2024 * 4.03B 323B Sales 2025 * 4.25B 340B Capitalization 17.83B 1,428B
Net income 2024 * 798M 63.88B Net income 2025 * 845M 67.64B EV / Sales 2024 * 4.29 x
Net cash position 2024 * 553M 44.28B Net cash position 2025 * 1.37B 110B EV / Sales 2025 * 3.88 x
P/E ratio 2024 *
22.8 x
P/E ratio 2025 *
21.2 x
Employees 6,990
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.49%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.36%
1 week+0.80%
Current month-2.54%
1 month-0.25%
3 months+2.11%
6 months+15.49%
Current year+6.34%
More quotes
1 week
74.89
Extreme 74.89
77.81
1 month
74.53
Extreme 74.53
79.22
Current year
70.53
Extreme 70.53
79.22
1 year
64.02
Extreme 64.02
87.88
3 years
59.78
Extreme 59.78
87.88
5 years
26.49
Extreme 26.49
87.88
10 years
20.28
Extreme 20.28
87.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 06/12/13
Director of Finance/CFO 54 31/12/05
Chief Operating Officer 44 31/08/17
Members of the board TitleAgeSince
Chief Executive Officer 60 06/12/13
Director/Board Member 69 14/05/17
Director/Board Member 63 30/11/16
More insiders
Date Price Change Volume
26/04/24 75.98 +0.36% 919,462
25/04/24 75.71 -1.30% 1,190,940
24/04/24 76.71 -0.62% 963,154
23/04/24 77.19 +1.27% 1,603,280
22/04/24 76.22 +1.11% 1,516,324

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
75.98 USD
Average target price
84.27 USD
Spread / Average Target
+10.92%
Consensus